Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Biogen Inc. closed 41.43% below its 52-week high of $238.00, which the company achieved on July 12th.

In a report released on February 7, Umer Raffat from Evercore ISI maintained a Buy rating on Biogen (BIIB – Research Report). The company’s ...

BofA lowered the firm’s price target on Biogen (BIIB) to $163 from $178 and keeps a Neutral rating on the shares. The firm calls Biogen “one of ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Real-time index price for Nasdaq Composite (NASX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...